Ratings Elanco Animal Health Incorporated

Equities

ELAN

US28414H1032

Delayed Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
16.28 USD +0.68% Intraday chart for Elanco Animal Health Incorporated -0.12% +9.26%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+9.26% 8.03B
B-
-3.76% 3.13B
B-
+4.62% 3.11B
B-
+9.80% 1.39B -
-21.25% 1.32B
C-
-20.24% 1.29B
B
-2.83% 1.27B -
-14.08% 1.13B -
+4.89% 950M
D+
-15.31% 888M -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock
  2. Equities
  3. Stock Elanco Animal Health Incorporated - Nyse
  4. Ratings Elanco Animal Health Incorporated